A newly approved gene therapy for Hemophilia B tops the charts as the most expensive therapy in the US. A round of the therapeutic, which provides substantial protection against bleeds with a single treatment, comes with a price of $3.5 million. The drugmaker CSL says that the steep price is justified.
According to Mariah Taylor, “The drug will be commercialized immediately at the price point of $3.5 million. According to a CSL statement, this will “generate significant cost savings for the overall healthcare system and significantly lower the economic burden of hemophilia B. The company estimates that people with moderate-to-severe hemophilia B can accumulate $20 million in treatment over a lifetime.”
To read more, click here.
(Source: Becker’s Hospital Review, November 23rd, 2022)